Compare Coursera Inc (COUR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Summit Therapeutics Inc — how do they compare? Coursera Inc trades at $5.16 (market cap $1.39B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 9.9× Coursera Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Summit Therapeutics Inc for 16 Days on average.
| COUR | SMMT | |
|---|---|---|
Market Cap | $1.39B | $13.71B |
Volume | 9,728,980 | 6,173,057 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $26.38 |
52-Week Low | $4.64 | $12.43 |
Typical Hold Time | 47 Days | 16 Days |
Enterprise Value | $648.49M | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COUR trades at $5.27, up 3.13% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages. Revenue growth is solid, rising from $524M in 2022 to $758M in 2025, yet the company remains unprofitable with a net loss of $51M in 2025. Recent news highlights AI platform developments and institutional interest, including large call option purchases and a new stake by Deutsche Bank AG.
The outlook is cautiously optimistic, driven by revenue growth and analyst consensus favoring a buy with a $7.40 price target. However, persistent losses, integration risks from acquisitions, and competitive pressures in edtech pose significant risks. Upside depends on converting subscriber growth into profitability.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
